Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01363817 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
A Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 6
- Study locations
NCT01363817: Completed Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma, sponsored by Bristol-Myers Squibb.
NCT01363817 is a Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01363817, a Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG BMS-906024
Study Locations (6)
Other
- Local Institution - Marseille
- Local Institution - Paris
- Johann Wolfgang Goethe Universitaet - Frankfurt am Main
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- The University Of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-09-28 |
| Est. Completion | 2018-02-07 |
| Phase | Phase 1 |
What the finished NCT01363817 record still lists
NCT01363817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 2 conditions, with Lymphoblastic Leukemia, Acute T-cell appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01363817 lists 6 locations in 4 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT01363817 about?
NCT01363817 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma". The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
What is the current status of trial NCT01363817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2011-09-28. Estimated completion is 2018-02-07.
What conditions does trial NCT01363817 study?
This clinical trial studies the following conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT01363817?
The interventions under investigation include: Dexamethasone (DRUG), BMS-906024 (DRUG).
Who is sponsoring clinical trial NCT01363817?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01363817 being conducted?
This trial has 6 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01363817's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI